Caldera Health will hold its Annual General Meeting at their premises on the 6th of December at 4pm to update shareholders of the considerable progress made in the last 12 months including interim results from Clinical Study 3 validating their diagnostic test for prostate cancer on urine samples.
A poster describing Caldera’s development of a urine vesicle based diagnostic test for prostate cancer will be presented by Dr. Nancy Frédérickx at the 2018 Australasian Extracellular Vesicles Conference. The conference, being held in Sydney, Australia on 14th-16th November, is a major gathering of Southern Hemisphere researchers working on extracellular vesicles (EV). It promises to […]
This pivotal study is designed to test the accuracy of the gene signatures from CS2b generated on prostate tissue in urine, allowing for the development of a highly accurate prostate cancer screening test that utilises the non-invasive sample source of urine. In total, Caldera will recruit a minimum of 300 donors who will donate matched […]
Caldera Health will hold its Annual General meeting at the end of November to update shareholders of the considerable progress made in the last 12 months including the successful completion of Clinical Study 2b confirming world class accuracy in tissue samples, and the start of Clinical Study 3.
Caldera will be participating in the TIKI (Technology Innovation and Knowledge Interchange) Tour hosted by the Ministry of Health in Wellington at the end of November in partnership with CMDT and MedTech CoRE. This is an innovation showcase to highlight the latest in healthcare technologies & research, and facilitate discussions with companies and researchers. The […]
Dr Keith Hudson, Director of Research and Development presented an update of Caldera’s development and an overview of the current clinical study at the Urological Society of Australia and New Zealand (USANZ) Conference in Tauranga. USANZ is the peak professional body for urological surgeons in Australia and New Zealand and the conference focussed on the […]
Rob Mitchell, Caldera Health CEO, presented at NZBIO as part of a session panel focussing on the NZ Medical Diagnostic start-up companies. The conference was an excellent opportunity to update the New Zealand bioscience community on Caldera’s progress and connect with local and international delegates across numerous biotech fields.
Caldera Health has expanded its commercial team with the appointment of Jennifer (Jen) Barnes as the head of Business Development to drive commercialisation of their prostate cancer biomarker assays. Jen is an experienced molecular diagnostics specialist, with over 15 years of experience in the clinical diagnostics field. She spent 12 years with Roche Diagnostics New […]